Effects of interleukin-1 on bone turnover in normal mice
- PMID: 2788075
- DOI: 10.1210/endo-125-3-1142
Effects of interleukin-1 on bone turnover in normal mice
Abstract
Interleukin-1 (IL-1) is a potent stimulator of osteoclastic bone resorption in vitro and causes hypercalcemia and increased osteoclastic resorption when infused into normal mice for 72 h. However, its longer term or local effects on bone turnover in vivo are unknown. To study these, we injected IL-1 alpha once daily for 3 days into the sc tissue over the calvariae of normal mice and examined its effects on calvarial bone morphology during the subsequent 4 weeks using quantitative histomorphometry. Increased bone resorption inside the calvariae and elevated plasma calcium concentrations were present 24 h after the last IL-1 injection. These early systemic effects were not prevented by indomethacin. During the following 3-4 weeks most of the bone on the injected side of the calvariae was resorbed by osteoclasts and was subsequently replaced by increased amounts of new bone. These longer term local effects on bone turnover were prevented by indomethacin. However, indomethacin did not prevent the formation of new bone inside the calvariae at sites of resorption induced by IL-1 independent of prostaglandin production. These findings indicate that IL-1 stimulates bone turnover systemically, independent of prostaglandin production, and that it has profound long term local effects on bone turnover that are mediated through prostaglandins.
Similar articles
-
Stimulation of prostaglandin E2 and bone resorption by recombinant human interleukin 1 alpha in fetal mouse bones.Biochem Biophys Res Commun. 1986 Jul 31;138(2):618-24. doi: 10.1016/s0006-291x(86)80541-1. Biochem Biophys Res Commun. 1986. PMID: 3488738
-
Interleukin-1 stimulates release of insulin-like growth factor-I from neonatal mouse calvaria by a prostaglandin synthesis-dependent mechanism.Endocrinology. 1992 Nov;131(5):2297-305. doi: 10.1210/endo.131.5.1425428. Endocrinology. 1992. PMID: 1425428
-
The effect of leukemia inhibitory factor on bone in vivo.Endocrinology. 1993 Mar;132(3):1359-66. doi: 10.1210/endo.132.3.8440191. Endocrinology. 1993. PMID: 8440191
-
Interleukin-6 does not stimulate bone resorption in neonatal mouse calvariae.J Bone Miner Res. 1991 Jan;6(1):3-8. doi: 10.1002/jbmr.5650060103. J Bone Miner Res. 1991. PMID: 2048428
-
The role of prostaglandins in bone in vivo.Prostaglandins Leukot Essent Fatty Acids. 1990 Nov;41(3):139-49. doi: 10.1016/0952-3278(90)90081-u. Prostaglandins Leukot Essent Fatty Acids. 1990. PMID: 2281118 Review.
Cited by
-
1-Hydroxyethylidene-1,1-bisphosphonate decreases the postovariectomy enhanced interleukin 1 secretion from peritoneal macrophages in adult rats.Calcif Tissue Int. 1991 Dec;49(6):403-6. doi: 10.1007/BF02555851. Calcif Tissue Int. 1991. PMID: 1818766
-
17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens.J Clin Invest. 1992 Mar;89(3):883-91. doi: 10.1172/JCI115668. J Clin Invest. 1992. PMID: 1541679 Free PMC article.
-
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1566-71. doi: 10.1073/pnas.97.4.1566. Proc Natl Acad Sci U S A. 2000. PMID: 10677500 Free PMC article.
-
Bone resorption induced by parathyroid hormone is strikingly diminished in collagenase-resistant mutant mice.J Clin Invest. 1999 Feb;103(4):517-24. doi: 10.1172/JCI5481. J Clin Invest. 1999. PMID: 10021460 Free PMC article.
-
Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice.J Clin Invest. 1994 Dec;94(6):2397-406. doi: 10.1172/JCI117606. J Clin Invest. 1994. PMID: 7989596 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
